Jiangsu Cowin Biotech Co Ltd
688426
Company Profile
Business description
Jiangsu Cowin Biotech Co Ltd is a national high-tech enterprise with independent intellectual property rights based in the field of life sciences. It provides innovative biological products and services to in vitro diagnostic users. The product line mainly includes molecular diagnostic raw materials enzymes, nucleic acid collection and protection agents, nucleic acid extraction kits, molecular diagnostic detection reagents and others.
Contact
No. 1 Yaocheng Avenue
4th Floor, TQB Building
Jiangsu Province
Taizhou225300
CHNT: +86 52386201353
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
770
Stocks News & Analysis
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.
stocks
ASX energy share remains cheap despite strong outlook
Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.
stocks
Moated AI-proof tech play hiding in the ASX 100
ChatGPT and large language models should be a tailwind for this company.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,966.10 | 59.30 | -0.66% |
| CAC 40 | 8,227.32 | 70.89 | 0.87% |
| DAX 40 | 24,155.45 | 39.45 | -0.16% |
| Dow JONES (US) | 49,310.32 | 179.71 | -0.36% |
| FTSE 100 | 10,457.01 | 19.45 | -0.19% |
| HKSE | 25,678.44 | 236.76 | -0.91% |
| NASDAQ | 24,438.50 | 219.06 | -0.89% |
| Nikkei 225 | 59,446.98 | 306.75 | 0.52% |
| NZX 50 Index | 12,850.26 | 34.67 | -0.27% |
| S&P 500 | 7,108.40 | 29.50 | -0.41% |
| S&P/ASX 200 | 8,740.60 | 58.00 | -0.66% |
| SSE Composite Index | 4,069.44 | 23.81 | -0.58% |